Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

NCT06683950 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Age-related Macular Degeneration (ARMD)

Interventions

DRUG: Aflibercept 8mg

Sponsor

Kim's Eye Hospital